ArticleEndocrinology, diabetes & metabolism2026
Corticotroph Tumour Type Influences Clinical Behaviour in Patients With Nonfunctioning Pituitary Neuroendocrine Tumours.
Article in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Corticotroph Tumour Type Influences Clinical Behaviour in Patients With Nonfunctioning Pituitary Neuroendocrine Tumours.Endocrinology, diabetes & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThis study aims to describe whether the clinical behaviour of nonfunctioning pituitary neuroendocrine tumours/nonfunctioning pituitary adenomas (NF-PitNETs/NFPAs) is affected by pituitary cell lineage differentiation, focusing on patients with silent corticotroph tumours (SCTs) and silent gonadotroph tumours (SGTs).
methodsPatients (N = 101) who underwent primary surgery for NF-PitNETs/NFPAs from August 2014 to March 2020 at Uppsala University Hospital were included. Data on sex, age, MRI, pituitary function and immunohistochemical analysis of anterior pituitary hormone and transcription factor expression, were explored.
resultsSeventy-three patients had SGTs, and 18 had SCTs. Binary logistic regression revealed that having SCT versus SGT (OR 6.41 (CI: 1.20-34.42), p = 0.03), being older at the time of surgery (OR 1.07 (CI: 1.02-1.12), p = 0.01), and having a larger preoperative tumour volume (OR 1.17 (CI: 1.04-1.32), p = 0.01) were associated with an increased likelihood of postoperative pituitary failure. Patients with preoperative pituitary failure were older at the time of surgery (p = 0.01) and more often had preoperative elevation of prolactin levels (p = 0.01) than patients without preoperative pituitary failure. SCT patients were younger at the time of surgery than SGT patients (p = 0.003), but no significant difference in preoperative tumour volume was detected.
conclusionThe results indicate that cell lineage differentiation in NF-PitNETs/NFPAs influences clinical behaviour. Patients with SCTs were younger at the time of surgery, and harbouring a SCT was associated with an increased likelihood of having postoperative pituitary failure. These findings emphasise the importance of routine immunohistochemical analyses of anterior pituitary hormone and transcription factor expression to identify silent corticotroph tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.